(MedPage Today) — Topline data showed that an investigational gene therapy slowed Huntington’s disease progression and met its primary endpoint in a pivotal trial, uniQure Biopharma announced Wednesday.
A high-dose version of the treatment, known…
Source link : https://www.medpagetoday.com/neurology/generalneurology/117633
Author :
Publish date : 2025-09-24 21:19:00
Copyright for syndicated content belongs to the linked Source.
